RxDoctor Payments Data

Ankur Shah, MD

Cardiovascular Disease · Chicago, ILNPI 1942466362

Payments from drug & device makers

$5,974in general payments, 2019–2025

Across 94 payments — averaging $63.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Boston Scientific$978
  • Sanofi-aventis U.S. LLC$121
  • Pfizer$76
  • Actelion Pharmaceuticals US, Inc.$57
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$54
  • plus $379 from 12 others

What the payments were for

  • Travel & lodging$3,21554%
  • Food & beverage$2,75946%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,974 in reported general payments places this provider in the 70th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$291,661
Medicare patients
2,863
Services billed
5,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban299$363,755
EntrestoSacubitril/Valsartan41$61,850
XareltoRivaroxaban27$35,294
Repatha SureclickEvolocumab47$29,114
JardianceEmpagliflozin11$12,709
Metoprolol Succinate402$5,744
Atorvastatin Calcium266$2,466
Rosuvastatin Calcium171$2,340
Carvedilol116$1,270
Amlodipine Besylate128$1,095
Ezetimibe69$1,066
Losartan Potassium74$992
Lisinopril100$723
Potassium Chloride16$522
Nifedipine ErNifedipine19$451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$363,755299 claims
NovartisEntresto$29$61,85041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →